# A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor

> **NCT01128842** · PHASE1 · COMPLETED · sponsor: **Puma Biotechnology, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Advanced Malignant Solid Tumors

## Interventions

- **DRUG:** Neratinib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01128842
- **Lead sponsor:** Puma Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01128842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01128842, "A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01128842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*